FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
This article was originally published in The Tan Sheet
Executive Summary
FDA will continue to take actions against dietary supplement products prompted by a lower tolerance for adverse events than for other types of products, a policy reflected in its request for a recall the Hydroxycut weight-loss product line
You may also be interested in...
Supplements' Mandatory Adverse Event Reporting Portends Cosmetics' Potential Future
Supplement firms' reports of serious adverse events jump since becoming mandatory in 2008 and FDA warnings on failures to report have been on the rise as companies labor to keep up with investigations and reporting duties. Similar challenges could lie ahead for cosmetics firms under House and Senate bills.
FDA Needs To Track Actions Built On Supplement AERs – GAO Report
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.
FDA Needs To Track Actions Built On Supplement AERs – GAO Report
A GAO report says FDA “may be able to expand” its use of supplement adverse event reports if it can track its use of the data to support actions it takes to protect consumers. The report makes five key recommendations for the agency to improve its approach to AERs.